n-((2-3-dihydro-1-4-benzodioxin-2-yl)methyl)-5-methoxy-1h-indole-3-ethanamine and Syndrome

n-((2-3-dihydro-1-4-benzodioxin-2-yl)methyl)-5-methoxy-1h-indole-3-ethanamine has been researched along with Syndrome* in 2 studies

Other Studies

2 other study(ies) available for n-((2-3-dihydro-1-4-benzodioxin-2-yl)methyl)-5-methoxy-1h-indole-3-ethanamine and Syndrome

ArticleYear
A clinical study to observe the efficacy and safety of Besunyen Detox Tea for constipation.
    Medicine, 2022, Sep-23, Volume: 101, Issue:38

    Functional constipation (FC) is a common functional gastrointestinal disease and is one of the most common outpatient diseases. The purpose of this study was to investigate the efficacy and safety of the traditional Chinese medicine Besunyen Detox Tea (BDT) for FC and to compare the effect of BDT between constipation patients with and non-dryness-heat syndrome.. This multicenter, prospective, observational registry study included 1000 participants diagnosed with FC. This study will collaborate with 3 comprehensive hospitals and 15 community hospitals and recruit patients into the registry between July 2022 and July 2023. After enrollment, we will collect the individual characteristics of each patient, anthropometric data and general condition, bowel movement, patient assessment of constipation symptoms, patient assessment of constipation quality of life, TCM syndrome scale, and time to take the laxative product again after treatment. We will also record adverse events and economic indicators at each visit.. This is the first registry-based study to collect real-world data of participants diagnosed with FC receiving BDT treatment. The results of this registry may also reflect these characteristics and provide direct clinical evidence to verify the importance of syndrome differentiation and treatment for the use of TCM health care products.

    Topics: Constipation; Dioxins; Humans; Laxatives; Prospective Studies; Quality of Life; Syndrome; Tea; Tryptamines

2022
Development of a multi-year white-nose syndrome mitigation strategy using antifungal volatile organic compounds.
    PloS one, 2022, Volume: 17, Issue:12

    Pseudogymnoascus destructans is a fungal pathogen responsible for a deadly disease among North American bats known as white-nose syndrome (WNS). Since detection of WNS in the United States in 2006, its rapid spread and high mortality has challenged development of treatment and prevention methods, a significant objective for wildlife management agencies. In an effort to mitigate precipitous declines in bat populations due to WNS, we have developed and implemented a multi-year mitigation strategy at Black Diamond Tunnel (BDT), Georgia, singly known as one of the most substantial winter colony sites for tricolored bats (Perimyotis subflavus), with pre-WNS abundance exceeding 5000 individuals. Our mitigation approach involved in situ treatment of bats at the colony level through aerosol distribution of antifungal volatile organic compounds (VOCs) that demonstrated an in vitro ability to inhibit P. destructans conidia germination and mycelial growth through contact-independent exposure. The VOCs evaluated have been identified from microbes inhabiting naturally-occurring fungistatic soils and endophytic fungi. These VOCs are of low toxicity to mammals and have been observed to elicit antagonism of P. destructans at low gaseous concentrations. Cumulatively, our observations resolved no detrimental impact on bat behavior or health, yet indicated a potential for attenuation of WNS related declines at BDT and demonstrated the feasibility of this novel disease management approach.

    Topics: Animals; Antifungal Agents; Chiroptera; Humans; Nose; Syndrome; Volatile Organic Compounds

2022